HK1170809A1 - Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc - Google Patents

Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc

Info

Publication number
HK1170809A1
HK1170809A1 HK12111585.4A HK12111585A HK1170809A1 HK 1170809 A1 HK1170809 A1 HK 1170809A1 HK 12111585 A HK12111585 A HK 12111585A HK 1170809 A1 HK1170809 A1 HK 1170809A1
Authority
HK
Hong Kong
Prior art keywords
sparc
chemotherapy
antibodies
predict response
predict
Prior art date
Application number
HK12111585.4A
Other languages
English (en)
Chinese (zh)
Inventor
.德留
.德賽
.瑙爾
Original Assignee
阿布拉西斯生物科學有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿布拉西斯生物科學有限責任公司 filed Critical 阿布拉西斯生物科學有限責任公司
Publication of HK1170809A1 publication Critical patent/HK1170809A1/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12111585.4A 2009-05-28 2012-11-15 Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc HK1170809A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18208109P 2009-05-28 2009-05-28
PCT/US2010/036615 WO2010138839A2 (en) 2009-05-28 2010-05-28 Use of 2 anti-sparc antibodies to predict response to chemotherapy

Publications (1)

Publication Number Publication Date
HK1170809A1 true HK1170809A1 (en) 2013-03-08

Family

ID=43223381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111585.4A HK1170809A1 (en) 2009-05-28 2012-11-15 Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc

Country Status (14)

Country Link
US (2) US8383358B2 (ja)
EP (1) EP2435068B1 (ja)
JP (1) JP5886191B2 (ja)
KR (1) KR20120024794A (ja)
CN (1) CN102460168B (ja)
AU (1) AU2010253747B2 (ja)
BR (1) BRPI1014392A2 (ja)
CA (3) CA2763950C (ja)
ES (1) ES2533343T3 (ja)
HK (1) HK1170809A1 (ja)
IL (1) IL216580A (ja)
MX (1) MX2011012657A (ja)
WO (1) WO2010138839A2 (ja)
ZA (1) ZA201108999B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2630963A1 (en) * 2010-03-11 2013-08-28 Abraxis BioScience, LLC SPARC angiogenic domain and methods of use
KR20130086546A (ko) * 2010-06-03 2013-08-02 아브락시스 바이오사이언스, 엘엘씨 암 치료에 있어 sparc 미세환경 시그니처의 용도
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CA2802143C (en) 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Sparc encoding polynucleotide as a cancer therapy sensitizer
CA2530748A1 (en) * 2003-06-24 2005-02-24 Johns Hopkins University Methylated gene biomarkers for detecting cancer
CN105316405A (zh) * 2003-07-17 2016-02-10 环太平洋生物技术有限公司 用于胃癌检测的标记物
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
US20100069298A1 (en) 2008-09-16 2010-03-18 Robert Penny Methods for Detecting Overexpression of SPARC and Therapeutic and Diagnostic Methods Relating to Same
KR20120092597A (ko) 2009-09-18 2012-08-21 아브락시스 바이오사이언스, 엘엘씨 암 치료에 있어 sparc 미세환경 시그니처의 용도

Also Published As

Publication number Publication date
KR20120024794A (ko) 2012-03-14
CA2763950A1 (en) 2010-12-02
US8383358B2 (en) 2013-02-26
EP2435068B1 (en) 2015-03-04
CN102460168A (zh) 2012-05-16
MX2011012657A (es) 2012-01-12
CN102460168B (zh) 2015-05-20
BRPI1014392A2 (pt) 2016-04-05
EP2435068A4 (en) 2013-03-27
AU2010253747A1 (en) 2011-12-15
ES2533343T3 (es) 2015-04-09
US20130172261A1 (en) 2013-07-04
ZA201108999B (en) 2013-05-29
JP2012528337A (ja) 2012-11-12
WO2010138839A3 (en) 2011-03-03
JP5886191B2 (ja) 2016-03-16
WO2010138839A9 (en) 2011-01-13
CA2960887A1 (en) 2010-12-02
US9091697B2 (en) 2015-07-28
IL216580A0 (en) 2012-02-29
WO2010138839A2 (en) 2010-12-02
CA2853810C (en) 2017-04-25
IL216580A (en) 2015-11-30
CA2763950C (en) 2015-11-24
AU2010253747B2 (en) 2013-07-11
EP2435068A2 (en) 2012-04-04
CA2853810A1 (en) 2010-12-02
CA2960887C (en) 2018-09-04
US20100310507A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
IL255300A0 (en) Antibodies to matrix metalloproteinase 9 (mmp9)
EP2504031A4 (en) ANTI-IL-6 ANTIBODIES AND THEIR USE
IL232276A0 (en) Antibodies to 6-il and their uses
HK1217711A1 (zh) 特異於鈣粘素- 的抗體
IL216085A0 (en) Selective access to cryopreserved samples
IL214779A0 (en) Fully human antibodies specific to cadm1
EP2125890A4 (en) ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
EP2212431A4 (en) ANTI-IREM-1 ANTIBODIES
EP2582628A4 (en) ALKALIFIC SYNTHESIS OF ZEOLITE MATERIALS WITH LEV STRUCTURE
GB2496104B (en) Improvements in or relating to reading of assays
HK1170809A1 (en) Use of 2 anti-sparc antibodies to predict response to chemotherapy sparc
IL216444A (en) Chemo-enzymatic approach to the synthesis of pimcrolimus
TWM370966U (en) Structure of travel backpack
TWM370683U (en) Improved counter weight structure of pipe
TWM401082U (en) Improved structure of faucet to swing vertically
TH129814B (th) แอนติบอดีต่อ nr10 และการใช้ประโยชน์ของมัน
TWM373987U (en) Structural improvement of faucet
PL390096A1 (pl) Zastosowanie olejku eterycznego do zwalczania roztoczy
PL390098A1 (pl) Zastosowanie olejku eterycznego do zwalczania roztoczy
TWM401724U (en) Improved structure of faucet with dual temperatures

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190527